Summary

Salvage treatment combining paclitaxel and bevacizumab was feasible and improved outcomes in heavily pretreated patients with advanced, chemoresistant small cell lung cancer (SCLC) in a small single-center study conducted by the Hellenic Oncology Research Group. Safety concerns were an issue with these patients, who had poor prognoses and few treatment options.